115.26
전일 마감가:
$112.77
열려 있는:
$112.41
하루 거래량:
1.82M
Relative Volume:
0.28
시가총액:
$143.03B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
22.96
EPS:
5.02
순현금흐름:
$9.37B
1주 성능:
+1.87%
1개월 성능:
+2.33%
6개월 성능:
-0.31%
1년 성능:
+46.10%
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
GILD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GILD
Gilead Sciences Inc
|
115.27 | 139.93B | 28.80B | 6.31B | 9.37B | 5.02 |
![]()
LLY
Lilly Eli Co
|
730.58 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
![]()
JNJ
Johnson Johnson
|
179.03 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
![]()
ABBV
Abbvie Inc
|
212.39 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
![]()
NVS
Novartis Ag Adr
|
130.35 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
![]()
MRK
Merck Co Inc
|
84.47 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
2025-08-08 | 업그레이드 | Truist | Hold → Buy |
2025-07-25 | 업그레이드 | Needham | Hold → Buy |
2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
2025-03-04 | 재확인 | Oppenheimer | Outperform |
2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2024-12-10 | 재개 | BofA Securities | Buy |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-11-14 | 개시 | Citigroup | Buy |
2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2024-10-17 | 개시 | Bernstein | Outperform |
2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2024-05-01 | 재확인 | Maxim Group | Buy |
2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
2023-11-09 | 개시 | Deutsche Bank | Hold |
2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
2023-09-06 | 개시 | HSBC Securities | Reduce |
2023-07-24 | 재확인 | Barclays | Equal Weight |
2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-04-28 | 재개 | Piper Sandler | Overweight |
2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2022-12-13 | 재개 | BofA Securities | Neutral |
2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
2022-10-28 | 재확인 | Cowen | Outperform |
2022-10-28 | 재확인 | JP Morgan | Overweight |
2022-10-28 | 재확인 | Jefferies | Buy |
2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
2022-10-28 | 업그레이드 | Truist | Hold → Buy |
2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
2022-02-02 | 재확인 | BofA Securities | Neutral |
2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
2022-02-02 | 재확인 | Truist | Hold |
2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
2022-01-28 | 업그레이드 | Argus | Hold → Buy |
2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-12-09 | 재개 | Wells Fargo | Equal Weight |
2021-12-06 | 개시 | Goldman | Neutral |
2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2021-11-19 | 재개 | Piper Sandler | Neutral |
2021-10-20 | 재개 | Cowen | Outperform |
2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
2020-10-28 | 개시 | UBS | Neutral |
2020-09-30 | 재개 | Jefferies | Buy |
2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
2020-07-31 | 재확인 | Credit Suisse | Neutral |
2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
2020-07-31 | 재확인 | Piper Sandler | Overweight |
2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
2020-07-31 | 재확인 | SunTrust | Hold |
2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo - BioPharma Dive
Gilead Announces Partnership With PEPFAR - Contract Pharma
Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace
Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media
What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser
Gilead breaks ground on AI-enabled US manufacturing hub - European Pharmaceutical Review
Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest
Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance
Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser
Price action breakdown for Gilead Sciences Inc.2025 Volatility Report & Long-Term Growth Stock Strategies - Newser
Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest
What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser
Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations - Seeking Alpha
US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters
Gilead partners with PEPFAR to expand HIV prevention access - Investing.com
U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report
Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse
Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com
Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire
'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals
Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma
Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech
Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers
Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire
Gilead, Amgen kick off facility investments in US - pharmaphorum
Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com
Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma
Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace
Is Gilead Sciences Stock Underperforming the Nasdaq? - MSN
Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com
GILD Stock Quote Price and Forecast - CNN
Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4
Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters
Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest
Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma
Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com
Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest
Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox
Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest
4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences
Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener
Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest
Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha
Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com
Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest
Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider
Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser
Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):